Ramji Krishnan

Dr. Ramji Krishnan has over 25 years of experience in biologics, cell and gene therapy development, and commercialization. He began his career as a bench scientist and progressed into leadership roles spanning multiple functions, including manufacturing, regulatory sciences, process and analytical development, supply chain, and engineering. Most recently, he served as the Chief Technology Officer (CTO) at Celularity, where he was responsible for the technical development of CRISPR-based genetic engineering tools for allogeneic cell therapies, including CAR-T and CAR-NK cells.

Prior to that, Dr. Krishnan led Manufacturing, MSAT and all CMC technical development for both AAV (AAV9) and autologous Hematopoietic Stem Cell (CD34+) therapies at Rocket Pharmaceuticals. In his role at Celgene, prior to its acquisition by Bristol-Myers Squibb (BMS), he was the Global Head of Biologics MSAT. Dr. Krishnan began his career at BMS, supporting product development, approval, and lifecycle activities as a technical and regulatory lead for several products, including Reblozyl, Opdivo, Myalept, Yervoy, Nulojix, Orencia IV, and Orencia Sub-Q.

Dr. Krishnan's passion lies in creating positive patient outcomes through product development. He is dedicated to finding optimal solutions and helping teams collaborate strategically to achieve clinical, regulatory and commercial success.